Events

Presentation by Jake Higgins, PhD
Rapid, High Precision Identification of Relative Sensitivity of Different Resistance Mutations to TKI Therapies using In Vitro Competition and Ultra-Accurate Duplex Sequencing

Presentations and Posters featuring TwinStrand Duplex Sequencing™ Technology

• Adapting Next-Generation Genetic Toxicology Endpoints to the Human In Vitro Air-Liquid-Interface Airway Tissue Model, Yiying Wang, FDA/NCTR
• Adopting Duplex Sequencing Technology for Genetic Toxicity Testing: A Proof-of-Concept Mutagenesis Experiment with N-Ethyl-N-Nitrosourea (ENU)- Exposed Rats, Stephanie Smith-Roe, National Toxicology Program
• Comparison of Duplex Sequencing and CarcSeq Error-Corrected NGS methods for Detection of Preneoplastic Clonal Expansions in Normal, Healthy Human Tissues, Meagan Myers, PhD, DHHS/FDA/NCTR
• Duplex Sequencing™ Demonstrates Dose-related Increases in Mutation Frequencies and C>A Transitions in the Bone Marrow of MutaMouse Males Exposed to Benzo(a)pyrene. LeBlanc, D. et al.
• Error-Corrected Duplex Sequencing; Bioinformatic Challenges, Clint Valentine, TwinStrand
• Extension of Error-Corrected Duplex Sequencing to Structural Variant Detection, Thomas E. Wilson, MD, PhD, University of Michigan Medical School
• Interspecies Comparison of Chemical-induced Mutagenesis by Duplex Sequencing, Bob Young, Millipore-Sigma
• Ultra-Deep Sequencing of Blood and Urine to Test for Exposure to Aristolochic Acids, Arnoud Boot, Duke-NUS Medical School

Virtual Presentation by CEO Jesse Salk, MD, PhD
“Ultrasensitive Genetic Detection: Below One-In-One-Million”

TwinStrand is a science-first genomics company based around Duplex Sequencing, an ultra-sensitive DNA analysis technology designed to improve cancer diagnostics. We use a combination of specialized biochemistry and powerful cloud-based computation to improve the accuracy of existing DNA sequencers by more than 10,000-fold. This unprecedented resolution lets us solve a variety of clinically actionable oncologic ‘needle in a haystack’ problems such as early detection of cancer, monitoring for residual tumor cells after therapy and identification of new chemicals and environmental exposures that put people at risk for cancer. We make it possible for researchers to see faint signals that were previously hidden, to help our collective effort to reduce global burden of cancer.

Official Launch of Duplex Sequencing^TM Technology

Presentation by CEO Jesse Salk, MD, PhD
Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Duplex Sequencing

View Talk

Poster Presented
Super CHIP: Duplex Sequencing Reveals Clonal Dynamics in Blood that are Magnitudes more Complex than Previously Recognized

View Poster

Presentation by CEO Jesse Salk, MD, PhD
Ultrasensitive Minimal Residual Disease Detection By Duplex Sequencing

Abstract
Duplex Sequencing enables an unprecedented level of NGS accuracy, with error rates below one-in-ten-million. The technology is ideally suited to detection of residual cancer (MRD), where lingering tumor cells are vastly outnumbered by normal cells. Here we present Duplex Sequencing-based MRD data from three clinical studies in acute myeloid leukemia.

Presentation by Jake Higgins
Clonal Landscapes of Hematologic Malignancies Redefined by Ultra-Sensitive Duplex Sequencing

View Poster Presented at Event

View Posters Presented and Abstract Information

Presentation by CEO Jesse Salk, MD, PhD
Genetic susceptibility and biologic markers of carcinogen exposure

View Posters Presented at Event

View Poster Presented at Event